Our UK work has a translational impact with clear patient benefits. We work to ensure that as treatments and a cure for Rett Syndrome become viable, they are accessible to patients in the UK. To this end, for the last four years, we have also funded the Clinical Research Team at King’s College London where the current UK clinical trial of Sarizotan is taking place. Based in Manchester, we are a small team working double time with minimal bureaucracy. We believe that to deliver treatments and a cure for Rett as quickly as possible, the funds we raise need to push research forward today. That’s why we deliberately hold no endowment or excessive reserves, instead seeking to deploy funds raised as quickly and wisely as possible. Donor contributions are typically deployed to research projects within three months or less.
The most important thing to remember is that there is hope. We know the gene that causes Rett and it’s a single one. Rett has already been reversed in the lab. We’re not raising money for something abstract, we’re working to bring treatments and a cure for Rett home.